Katkhouda N, Hurwitz M B, Rivera R T, Chandra M, Waldrep D J, Gugenheim J, Mouiel J
Department of Surgery, University of Southern California School of Medicine, Los Angeles, USA.
Ann Surg. 1998 Oct;228(4):568-78. doi: 10.1097/00000658-199810000-00013.
To study the safety and efficacy of laparoscopic splenectomy (LS) in patients with predominantly benign hematologic disorders.
The technical feasibility of LS has been recently established. However, data regarding the efficacy of the procedure in a large cohort of patients are scarce.
One hundred three consecutive patients underwent LS between June 1992 and October 1997. Data were collected prospectively on all patients.
Indications were idiopathic thrombocytopenic purpura (ITP), hereditary spherocytosis, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and others. Mean spleen size was 14 cm and mean weight was 263 g. Accessory spleens were found in 12 patients with ITP and in 5 patients without ITP. There were no deaths. Complications occurred in six patients, one requiring a second procedure for small bowel obstruction. Six patients received transfusions, and four procedures were converted to open splenectomy for bleeding. Mean surgical time was 161 minutes and was greater in the first 10 cases than the last 10. Mean postsurgical stay was 2.5 days. Thrombocytopenia resolved after surgery in 84% of patients with ITP, and hematocrit levels increased significantly in 70% of patients with chronic hemolytic anemias. A positive response was noted in 92% of patients with hereditary spherocytosis, without relapse for the duration of the observation. ITP relapsed in four patients during follow-up, three within 12 months.
LS can be performed safely and effectively in a teaching institution. Rigorous technique will minimize capsular fractures, reducing the risk of splenosis. Accessory spleens can be successfully localized, thus improving response and limiting recurrence of ITP. LS should become the technique of choice for treatment of intractable benign hematologic disease.
研究腹腔镜脾切除术(LS)治疗以良性血液系统疾病为主的患者的安全性和有效性。
最近已证实LS在技术上是可行的。然而,关于该手术在大量患者中的疗效数据却很匮乏。
1992年6月至1997年10月期间,连续103例患者接受了LS。对所有患者进行前瞻性数据收集。
手术适应证包括特发性血小板减少性紫癜(ITP)、遗传性球形红细胞增多症、自身免疫性溶血性贫血、血栓性血小板减少性紫癜等。脾脏平均大小为14 cm,平均重量为263 g。在12例ITP患者和5例非ITP患者中发现了副脾。无死亡病例。6例患者出现并发症,1例因小肠梗阻需要再次手术。6例患者接受了输血,4例手术因出血转为开放性脾切除术。平均手术时间为161分钟,前10例的手术时间比后10例长。术后平均住院时间为2.5天。84%的ITP患者术后血小板减少症得到缓解,70%的慢性溶血性贫血患者血细胞比容水平显著升高。92%的遗传性球形红细胞增多症患者有阳性反应,在观察期内无复发。4例患者在随访期间ITP复发,3例在12个月内复发。
在教学机构中,LS可以安全有效地进行。严格的技术操作将使包膜破裂降至最低,降低脾种植的风险。副脾能够成功定位,从而改善疗效并限制ITP的复发。LS应成为治疗难治性良性血液系统疾病的首选技术。